Investors

Overview

Corporate Profile

Gamida Cell is an advanced cell therapy company committed to finding cures for patients with blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest News

View All
Jan 11, 2021

Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR

Read More
Jan 05, 2021

Gamida Cell to Present at Upcoming January Investor Conferences

Read More
Dec 21, 2020

Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Read More
Dec 18, 2020

Gamida Cell Added to NASDAQ Biotechnology Index

Read More
Dec 17, 2020

Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary Shares

Read More
Dec 16, 2020

Gamida Cell Announces Launch of Public Offering of Ordinary Shares

Read More
Dec 14, 2020

Gamida Cell Provides Regulatory Update on Biologics License Application for Omidubicel

Read More
Dec 09, 2020

Gamida Cell Provides Pipeline Update, Including Detailed Results of Pivotal Phase 3 Clinical Study of Omidubicel, and Prepares to Start BLA Submission by End of 2020

Read More
Dec 05, 2020

Gamida Cell Presents Updated, Expanded Results from Phase 1 Study of Natural Killer Cell Therapy GDA-201 at ASH Annual Meeting and Exposition

Read More
Dec 02, 2020

Gamida Cell to Host Virtual Pipeline Deep Dive

Read More
Nov 24, 2020

Gamida Cell to Present at Upcoming Conferences

Read More
Nov 10, 2020

Gamida Cell Reports Third Quarter 2020 Financial Results and Provides Company Update

Read More
Nov 04, 2020

Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual Meeting

Read More
Nov 04, 2020

Gamida Cell to Present at H.C. Wainwright 6th Annual Israel Conference

Read More
Nov 02, 2020

Gamida Cell Announces the Date of Its Third Quarter 2020 Financial Results and Webcast

Read More
Oct 13, 2020

Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration

Read More
Oct 07, 2020

Gamida Cell to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

Read More
Oct 06, 2020

Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies

Read More
Sep 10, 2020

Gamida Cell Presents Analysis of Observational Data Demonstrating the Impact of Donor Age in Hematopoietic Stem Cell Transplant Outcomes at the Virtual Cord Blood Connect Meeting

Read More
Sep 08, 2020

Gamida Cell to Participate in Upcoming Investor Conferences

Read More
Upcoming Events
More events are coming soon.
Recent Events
Corporate Fact Sheet
Corporate Presentation

Investor & Media Contact

Josh Hamermesh
Chief Business Officer
Gamida Cell Ltd.
IRPR@gamida-cell.com